Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05879250 · ClinicalTrials.gov registry record · Phase 2

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma, sponsored by Northwestern University.

Recruiting
Registry status
Phase 2
Development phase
39
Enrollment target
2
Study locations

NCT05879250 is a Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 39 participants, below the 275-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05879250, a Phase 2 study of Glioblastoma, IDH-wildtype and MGMT-Unmethylated Glioblastoma, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
Phase 2
Development phase
39 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.

Conditions Studied

Glioblastoma, IDH-wildtype MGMT-Unmethylated Glioblastoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • RADIATION Radiation Therapy
  • PROCEDURE Surgical Procedure
  • DRUG STAT3 Inhibitor WP1066

Study Locations (2)

Illinois

  • Northwestern University - Chicago
  • Northwestern Medicine: Warrenville - Warrenville

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2024-05-22
Est. Completion 2028-12-27
Phase Phase 2

Sponsor

Northwestern University

1,209 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05879250

The ClinicalTrials.gov registry entry for NCT05879250 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (86% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Glioblastoma, IDH-wildtype appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05879250 reports 2 study locations spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05879250 about?

NCT05879250 is a clinical study titled "WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma". This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multip...

What is the current status of trial NCT05879250?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-05-22. Estimated completion is 2028-12-27.

What conditions does trial NCT05879250 study?

This clinical trial studies the following conditions: Glioblastoma, IDH-wildtype, MGMT-Unmethylated Glioblastoma.

What interventions are being tested in trial NCT05879250?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Surgical Procedure (PROCEDURE), STAT3 Inhibitor WP1066 (DRUG).

Who is sponsoring clinical trial NCT05879250?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05879250 being conducted?

This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma, IDH-wildtype

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma, IDH-wildtype

All registered trials for this condition

MGMT-Unmethylated Glioblastoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.